Free tool
FAERS Monitor: Trijardy Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212614 or its brand name (Trijardy Xr, Empagliflozin, Linagliptin, Metformin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
124
Serious
45
36% of reports
Hospitalization
25
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased20
- off label use11
- fatigue10
- diarrhoea7
- headache6
- nausea6
- vomiting6
- weight decreased6
- dizziness5
- drug ineffective5
- glycosylated haemoglobin increased5
- decreased appetite4
- dyspnoea4
- impaired gastric emptying4
- product physical issue4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 4 |
| 2021 | 45 |
| 2022 | 23 |
| 2023 | 17 |
| 2024 | 14 |
| 2025 | 10 |
| 2026 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,035 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| impaired gastric emptyingSignal | 4 | 49.8 | 19.0 | 146 |
| product physical issueSignal | 4 | 33.6 | 12.8 | 96 |
| glycosylated haemoglobin increasedSignal | 5 | 33.6 | 14.2 | 127 |
| blood glucose increasedSignal | 20 | 18.0 | 12.1 | 307 |
| weight decreasedSignal | 6 | 3.6 | 1.7 | 9 |
| decreased appetite | 4 | 2.9 | 1.1 | 3 |
| fatigueSignal | 10 | 2.2 | 1.2 | 5 |
| vomiting | 6 | 2.2 | 1.0 | 3 |
| off label useSignal | 11 | 2.1 | 1.2 | 6 |
| diarrhoea | 7 | 1.8 | 0.9 | 2 |
| dizziness | 5 | 1.7 | 0.7 | 1 |
| headache | 6 | 1.6 | 0.7 | 1 |
| nausea | 6 | 1.3 | 0.6 | 0 |
| dyspnoea | 4 | 1.2 | 0.5 | 0 |
| drug ineffective | 5 | 0.6 | 0.3 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.